In a setback for research-based drugmakers, the U.S. Supreme Court declines to hear an appeal over patent rights for drugs prescribed for off-market uses.
Temporary restraining order bars Eon from selling generic version of GlaxoSmithKline antidepressant until trial date.
Eon is slated to go to trial with GlaxoSmithKline on Dec. 9 over drug patents, but had planned to launch generic version before trial's outcome.
Revised language would strip patents from legislation and remove criminal sanctions for copyright infringement.
Appeals court overturns lower court's ruling barring DLF from marketing generic version of Cipramil anti-depressant.
Generic drugmakers agree to share profits from diabetes 2 drug during 180-day exclusivity period.
World's largest law firm says IP group remains strong despite defection of practice head and two other partners to rival firm.
Tristrata to seek triple damages and attorneys' fees, as well as injunction to ban sales of infringing products.
Appeals court favors generics makers, upholding lower court's decision to invalidate antibiotic patent.
But judge rules J&J's Cordis is likely to prevail in patent suit on balloon expandable stents.
Australia should carefully review the way its patent laws cover genetic material to avoid being cut out of medical tests and future research, researchers advise commission.
In a setback for U.S. industry groups and Bush administration, final draft on Free Trade Area of the Americas leaves out agreement on hemisphere-wide intellectual property protection.
Ulcer drug has annual sales of $1.2 billion.
Lawsuit concerns patent for AstraZeneca's blockbuster Losec drug.
Foreign minister Kanwal Sibal defends India's intellectual property laws amid criticism from U.S. officials and industry groups.
University had sued DRAXIS over tablet for the treatment of cognitive disorders in dogs.
New study details losses resulting from counterfeiting drugs, consumer goods and auto parts.
Suit highlights rising tensions between U.S. drugmakers and overseas biotech licensing partners over royalty payments.
Australian biotech company remains in dispute with Applera.
Transactions are expected to grow sharply as Chinese drugmakers eye domestic and Asian markets.